Why the study?
Does subcutaneous enoxaparin as bridging anticoagulant treatment provide a safe profile in patients undergoing cardiac surgery?
Does subcutaneous enoxaparin as bridging anticoagulant treatment provide a safe profile in patients undergoing cardiac surgery?
Enoxaparin as a bridging anticoagulant in cardiac surgery shows a reasonable rate of adverse events, supporting its potential use pending randomized trials.
No takes yet. Share an insight, caveat, or question.
Acceptable event rates with enoxaparin bridging; hypothesis-generating and requires randomized trials before clinical adoption.
Rivas‐Gándara et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: